Chappell D B, Zaks T Z, Rosenberg S A, Restifo N P
Howard Hughes Medical Institute-NIH Research Scholars Program, Bethesda, Maryland 20814, USA.
Cancer Res. 1999 Jan 1;59(1):59-62.
A recent report described the expression of Fas ligand (FasL) by melanoma cells as an important mechanism involved in the immune evasion by tumors [M. Hahne et al., Science (Washington DC), 274: 1363-1366, 1996]. To investigate the expression of FasL by melanomas, we screened a panel of early-passage cell lines by functional assay and reverse transcriptase-PCR. Using conditions designed to replicate those in the original report, we did not find functional FasL on any of the 19 human melanoma lines established at the National Cancer Institute. Furthermore, we additionally evaluated our melanoma lines using reverse transcriptase-PCR and found that 0 of the 26 human melanoma cell lines expressed FasL mRNA. FasL mRNA was abundantly expressed by anti-melanoma T-cell lines after activation. These data do not support a role for FasL expression in the escape of melanoma cells from immune destruction.
最近的一份报告将黑色素瘤细胞中Fas配体（FasL）的表达描述为肿瘤免疫逃逸的一种重要机制[M. 哈内等人，《科学》（华盛顿特区），274: 1363 - 1366，1996]。为了研究黑色素瘤中FasL的表达，我们通过功能测定和逆转录聚合酶链反应筛选了一组早期传代细胞系。使用旨在复制原始报告中条件的方法，我们在美国国立癌症研究所建立的19个人类黑色素瘤细胞系中均未发现功能性FasL。此外，我们还使用逆转录聚合酶链反应对我们的黑色素瘤细胞系进行了评估，发现26个人类黑色素瘤细胞系中有0个表达FasL mRNA。抗黑色素瘤T细胞系激活后大量表达FasL mRNA。这些数据不支持FasL表达在黑色素瘤细胞逃避免疫破坏中起作用。
